Empowering Drug Development
through Epigenomics
The Virtuoso™ epigenomics platform, by ClearNote Health, measures active disease biology from drug discovery through development, including dynamic insights into therapy response and resistance, all through a simple blood draw. Learn more about the Virtuoso Epigenomics Platform.
Partner With Us
Epigenomic Expertise
The Virtuoso Platform represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical biological changes in plasma. By leveraging these capabilities, the Virtuoso Platform accelerates drug development and advances precision medicine.
Innovate in Drug Discovery
Leverage our unique genome-wide 5hmC profiling to gain insights into disease biology with liquid biopsies and uncover new drug targets.
Enhance Patient Selection
Employ our precision diagnostics to ensure targeted patient enrollment in clinical trials, optimizing outcomes.
Recognise Dynamic Therapy Response
Utilize our technology to identify patients most likely to benefit from new targets and to monitor for potential resistance.
Monitor Therapeutic Outcomes
Harness our advanced 5hmC analysis to track therapeutic efficacy and detect emergent resistance, guiding timely intervention strategies.
Revealing Biological Changes in Plasma
Traditional drug development processes are challenged by limited tissue availability and lack of tools that can capture tumor evolution and biology that is driven by non-genetic mechanisms. To address these challenges, ClearNote Health introduced the Virtuoso Epigenomics Platform, a groundbreaking whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology to empower drug discovery and development.